SynthesisTremor and other hyperkinetic movements (New York, N.Y.)2025
Movement Disorders in Neurocysticercosis: A Systematic Review.
Synthesis in Tremor and other hyperkinetic movements (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Movement Disorders in Neurocysticercosis: A Systematic Review.Tremor and other hyperkinetic movements (New York, N.Y.) · 2025Pooled it
- Neurocysticercosis in transition: expanding clinical spectrum, evolving diagnostics, and emerging therapies.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neurocysticercosis, caused by Methods: A comprehensive search of PubMed, Scopus, Embase, Web of Science, and Google Scholar was conducted to identify case reports, case series, and cohort studies reporting movement disorders in confirmed cases of neurocysticercosis. Included studies were assessed for clinical details, neuroimaging findings, cerebrospinal fluid results, type of movement disorder, treatment regimens, and outcomes. Quality assessment was done using Murad's framework for case reports. Results: A total of 45 patients were included: 21 presented with hypokinetic and 24 with hyperkinetic movement disorders. In the hypokinetic group, parkinsonism was the most common manifestation (52.38%) with basal ganglia and midbrain involvement. Levodopa was administered in 28.57%, and 47.62% achieved marked clinical improvement. In the hyperkinetic group, chorea (29.17%), facial dyskinesias (25%), and myoclonus (16.67%) were prevalent. Albendazole with corticosteroids was used in over 60% of cases, and 83.3% had full or marked recovery. Conclusions: Movement disorders in neurocysticercosis are diverse but potentially reversible. Early neuroimaging and targeted therapy yield favorable outcomes, especially in hyperkinetic presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.